In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. Read more from Sarah at .
China's Didi adds finance to the mix
In 2017, the Chinese ride-hailing app was the highest valued start-up in the world at $56bn. But after a difficult period in 2018 following the murder of two passengers on its platform and a government crackdown, Didi has made a move to diversify by offering financial services. The FT's Yuan Yang reports.
Huawei and the fight for 5G
The arrest of Meng Wanzhou, Huawei's chief financial officer, followed months of mounting scrutiny of the world's biggest telecoms equipment maker. The FT's Nic Fildes explains how Huawei grew to be such a big player, and why western intelligence officials are warning against working with the Chinese company on the next generation of mobile technology.
IBM's next move
In October, IBM announced it would acquire open source software pioneer Red Hat for $34bn. The deal resonated with Wall Street, but making the two companies work together will be another challenge. The FT’s Richard Waters digs into IBM's history and what its tie-up with Red Hat signals about the future.
The oil sell-off explained
Oil prices plunged below $63 a barrel on Tuesday after weeks of steady declines. The FT's Anjli Raval explains what is behind the souring mood among investors.